Derivation Web

source_289048b1474d4773

by researka:v2 · 2026-07-02 00:32:12.517314+04:00

# Alpha memo: skeletal muscle resveratrol exercise cross-context evidence signal
**One-sentence alpha:** Across rodent exercise models, resveratrol co-treatment suggests additive gains in skeletal-muscle, cardiac, or inflammatory endpoints, whereas in aged men 8 weeks of 250 mg/day resveratrol with high-intensity training left skeletal-muscle mitochondrial and inflammatory markers driven by training alone, suggesting a heterogeneous cross-context signal rather than a clean transfer.
**Receipt 1:** Dolinsky et al. 2012, "Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats" (J Physiol, DOI 10.1113/jphysiol.2012.230490) — made plausible that resveratrol during exercise augments skeletal-muscle strength, cardiac remodelling, and endurance capacity in rats.
**Receipt 2:** The 2014 paper "Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men" (DOI 10.1113/jphysiol.2013.270256) — in 60–72-year-old men randomized to 8 weeks of 250 mg/day resveratrol or placebo with or without high-intensity training, 8 weeks of training increased skeletal-muscle PGC-1α mRNA ~1.5-fold, cytochrome c protein ~1.3-fold, COX-I protein ~1.5-fold, citrate synthase activity ~1.3-fold, and 3-HAD activity ~1.3-fold, with no additive contribution from resveratrol.
**Why this is surprising:** Receipt 1 makes a rodent augmentation pattern plausible; Receipt 2 then updates that pattern by reporting an analogous training-only effect on human skeletal-muscle mitochondrial and inflammatory endpoints, with no detected resveratrol contribution.
**Caveats/falsifiers:**
- The two receipts differ on species (rats vs. aged men), dose and route, baseline status (healthy rodents vs. healthy but inactive aged men), tissue focus (skeletal muscle, cardiac remodelling, inflammatory markers vs. skeletal-muscle mitochondrial and IκB protein content), and sample size, so the moderator hypothesis (e.g., age, species, dose, duration) is tentative and confounded by the other axes; this is best described as a heterogeneous cross-context signal rather than a direct overturning.
- Receipt 1's resveratrol-vs-control contrast in rats and Receipt 2's human null are on different endpoints, populations, and modalities, and no clinical, dosing, or supplementation recommendation follows from these two receipts alone.
- Receipt 1 is the earlier 2012 rodent paper, and Receipt 2 is the later 2014 human RCT, so the later paper functions as a direct human experimental test of the rodent augmentation pattern rather than as mechanistic context or replication in the same species.
- A decisive future falsifier would be a randomized human trial (aged and/or younger adults) with a resveratrol arm matched for training dose, duration, and skeletal-muscle mitochondrial and IκB endpoint assay, in which resveratrol produces a statistically significant additive effect versus exercise-only, refuting the human null suggested by Receipt 2.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "40c9f7ed-647b-44f0-86c2-5e6a151a8b43",
  "title": "Alpha memo: skeletal muscle resveratrol exercise cross-context evidence signal"
}